Contact Dr. Lu for information about cancer treatments。聯繫盧博士，獲取有關癌症治療資訊。
Human breastmilk has long been considered “liquid gold” among clinicians treating premature infants in a newborn intensive care unit (NICU). Breastmilk-fed “preemies” are healthier, on average, than those fed formula. Why is that true, however, has remained a mystery.
New research from the University of Maryland School of Medicine’s (UMSOM) Institute for Genome Sciences (IGS), published online in the journal mBio in June found it is not just the content of breastmilk that makes the difference. It is also the way the babies digest it.
The research, led by Bing Ma, PhD, Assistant Professor of Microbiology and Immunology at UMSOM and a researcher at IGS, discovered a strain of the Bifidobacterium breve bacteria or B. breve in the gut of breastfed babies who received higher volumes of breastmilk than their counterparts. Those preemies had better nutrient absorption because they developed an intact intestinal wall, one week after birth. B. breve was much less prevalent in both formula-fed babies and breastfed babies with “leaky gut.” Babies with leaky gut do not develop a barrier to protect against bacteria and digested food from getting into the bloodstream. For the first time, the team also found that the way B. breve metabolizes breastmilk keeps breastfed babies healthier and allows them to gain weight by strengthening their underdeveloped intestinal barrier.
An immature or “leaky” gut can lead to necrotizing enterocolitis (NEC), which is the third leading cause of newborn death in United States and worldwide. In fact, NEC impacts up to 10 percent of premature babies with a devasting mortality rate as high as 50 percent.
“Our discovery could lead to promising and practical clinical interventions to strengthen the babies’ gut and, therefore, increase survival rates of the most vulnerable preemies,” said Dr. Ma.
Bifidobacterium in the gut or microbiome has long been known to have health benefits. It includes a diverse set of strains that have very different properties. Some strains are only found in adults; some are mostly in adolescence. One strain, Bifidobacterium infantis, has been seen predominantly in full-term infants.
The researchers followed 113 premature babies who were born between 24 and 32 weeks’ gestation. This study found Bifidobacterium breve (B. breve) only in preemies who had improved gut barrier function within one week after birth. Dr. Ma and her colleagues discovered that Bifidobacterium breve is genetically equipped to digest nutrients within the cell membrane rather than the more typical external digestion process in which bacteria secrete digestive enzymes onto nutrients to break them down.
At the most basic level, the gut microbiome in these breastfed preemies with more B. breve metabolizes carbohydrates differently than it does formula. The researchers say they hypothesize that this process of metabolism then strengthens and matures the intestinal barrier faster, protecting fragile newborns from disease.
“We now know that it is not the breastmilk alone that helps preemies develop their intestinal barrier faster,” Dr. Ma said. “We will need to find the best way to prophylactically administer B. breve early in life, rather than rely on transmission from breastmilk or even the mother’s gut or vaginal microbiota during the birthing process. This is especially critical in formula-fed preemies.”
Dr. Ma said that more studies are needed to determine if the B. breve originated in the breastmilk, gut, mother’s vagina, or even environment.
E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, University of Maryland, Baltimore, the John Z. and Akiko K. Bowers Distinguished Professor, and Dean at UMSOM said, “This research can have a far-reaching impact globally. It could ultimately save thousands of premature babies from permanent disability or death associated with an immature and permeable intestine that allows deadly bacteria in.”
Authors from the Institute for Genome Sciences include Dr. Ma; Michael France, PhD, Post-Doc Fellow; Elias McComb, BS, Research Technician; Lindsay Rutt, MS, Laboratory Research Manager; Pawal Gajer, PhD, Research Associate, Microbiology and Immunology; Li Fu, BS, Laboratory Research Specialist; Hongqiu Yang, PhD, Microbiome Service Laboratory; Mike Humphrys, MS, Microbiome Service Laboratory Director; Luke J. Tallon, BA, Executive Scientific Director, Maryland Genomics; Lisa Sadzewicz, PhD, Executive Director, Maryland Genomics Administration; and Jacques Ravel, PhD, Professor of Microbiology and Immunology, Associate Director, Genomics, and Interim Director, IGS.
Authors from other departments within the University of Maryland School of Medicine include Sripriya Sundararajan, MBBS, MD, Associate Professor of Pediatrics and Neonatal Director of OB-MFM Relations; Gita Nadimpalli, MD, PhD, MPH, Graduate Research Assistant; Jose M. Lemme-Dumit, PhD, Post-Doc Fellow, Pediatrics; Elise Janofsky, Pediatrics; Lisa S. Roskes, MD, Pediatrics; Marcela F. Pasetti, PhD, Professor of Pediatrics, Microbiology and Immunology; and Rose M. Viscardi, MD, Professor Emeritus of Pediatrics and Medicine.
This study was supported in part by a Gerber Foundation 2018 award (project identifier 6361), the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grant number R21DK123674), and the Institute for Clinical and Translational Research (ICTR) at the University of Maryland Accelerated Translational Incubator Pilot (ATIP) award.
The authors have no conflict of interest.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world — with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.3 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
About the Institute for Genome Sciences: The Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine has revolutionized genomic discoveries in medicine, agriculture, environmental science, and biodefense since its founding in 2007. IGS investigators research areas of genomics and the microbiome to better understand health and disease, including treatments, cures, and prevention. IGS investigators also lead the development of the new field of microbial forensics. IGS is a leading center for major biological initiatives currently underway including the NIH-funded Human Microbiome Project (HMP) and the NIAID-sponsored Genomic Sequencing Center for Infectious Diseases (GSCID). Follow us on Twitter @GenomeScience.
Method of Research
Subject of Research
Highly Specialized Carbohydrate Metabolism Capability in Bifidobacterium Strains Associated with Intestinal Barrier Maturation in Early Preterm Infants
Article Publication Date
The authors have no conflict of interest.